Tag: Alzheimer’s disease

Another Controversial Alzheimer’s Drug

A new treatment for Alzheimer's Disease is promising, but we're not there yet.

/ November 30, 2022

Can supplements improve memory and cognition?

Can you reduce the risk of cognitive decline with dietary supplements?

/ September 1, 2022

Fraud, Scientific Rigor, and Alzheimer’s Research

A stunning case of possible fraud in Alzheimer's research reinforces the need for scientific rigor at every level.

/ August 10, 2022

COVID Associated With Neurodegenerative Disorders

COVID infection has been associated with an increased risk of neurodegenerative and neurovascular disease - another reason to keep our eye on this serious illness.

/ June 29, 2022
Alzheimer's Disease

Medicare and Medicaid place restrictions on new Alzheimer’s drug, Aduhelm (aducanumab)

An important decision has been made about a controversial new drug to treat Alzheimer's disease.

/ January 20, 2022

Poor Science Reporting and Premature Enthusiasm

Press releases often outpace the data. Here are some examples of over-enthusiastic reporting on extremely preliminary research.

/ December 21, 2021

FDA’s Decision to Approve Aduhelm (aducanumab) for Alzheimer’s

Criticism of the FDA's decision to approve aducanumab for Alzheimer's disease.

/ July 7, 2021
Alzheimer's Disease

No evidence, no problem: A closer look at the aducanumab approval

Why did the FDA approve aducanumab, a drug that hasn't been shown to work?

/ June 10, 2021
Prions and Creutzfeldt‐Jakob disease

Can mRNA-based COVID-19 vaccines cause prion disease or Alzheimer’s?

Antivax immunologist J. Bart Classen published a paper claiming that mRNA-based COVID-19 vaccines can cause prion disease leading to neurodegenerative diseases like Alzheimer's dementia. What are prions, and can these vaccines cause prion disease? (Spoiler alert: The answer to the second question is almost certainly no. It's speculation based on highly implausible biology.)

/ February 22, 2021
One Million Dollars

Would you pay $1 million to enroll in a phase 1 clinical trial of an “anti-aging” gene therapy?

Libella Gene Therapeutics, LLC made the news last week for announcing a "pay-to-play" trial of its telomerase-based anti-aging gene therapy. What was shocking about the announcement was not that it was a "pay-to-play" trial, given that such trials have become all too common, but rather the price of enrollment: $1 million. Worse, the trial is being conducted in Colombia; the therapy doesn't...

/ December 2, 2019